Sharekhan

Piramal Pharma Ltd

Tue 1/07/2025,14:49:59 NSE: PPLPHARMA

₹ 203.59 0.21 (0.10%)
BUY NOW Buy Piramal Pharma Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Piramal Pharma Ltd

Tue 1/07/2025,15:2:0

Piramal Pharma Ltd

Tue 1/07/2025,14:49:59 | NSE : PPLPHARMA

₹ 203.590.21 (0.10%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 204.10

Previous Close

₹ 203.38

Volume

1951665

Mkt Cap ( Rs. Cr)

₹27062.16

High

₹ 205.00

Low

₹ 201.12

52 Week High

₹ 307.90

52 Week Low

₹ 145.25

Book Value Per Share

₹ 59.53

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Piramal Pharma Ltd

Your Vote -

Buy

64.48%

Hold

11.58%

Sell

23.94%

64.48%

259 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

38%

Sell Order Quantity

62%

Bid Price

Qty

204.39

10

204.00

41

204.00

75

204.00

326

204.00

277

Bid Total

655875

Bid Price

Qty

204.44

10

204.00

10

204.00

1237

204.00

559

204.00

1566

Bid Total

1087948

Option Chain

Analyzes market sentiment, predicts Piramal Pharma Ltd' movement.

Call Price Open interest Strike Price Put Price Open interest

News

Media spotlight triggers stock stock attention, sentiment.

  • Piramal Pharma - Disclosure under SEBI Takeover Regulations

    26 Jun 2025, 8:22PM Piramal Pharma Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substa

  • Piramal Pharma - Copy of Newspaper Publication

    26 Jun 2025, 7:17PM Piramal Pharma Limited has informed the Exchange about Copy of Newspaper Publication

  • Piramal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    17 Jun 2025, 11:28AM PIRAMAL PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen

  • Piramal Pharma has declared 1.40% Final dividend for the financial year March 2025

    17 Jun 2025, 4:10PM Piramal Pharma Ltd. on Wednesday, 14 May 2025, has announced Final dividend of 1.40 percent on Equity Share, to its shareholders holding shares on the

  • Piramal Pharma - Corporate Action-Board to consider Dividend

    13 Jun 2025, 6:04PM Intimation of Record Date for payment of Final Dividend

  • Piramal Pharma - Intimation Of Record Date For Payment Of Final Dividend

    13 Jun 2025, 6:02PM Intimation of Record Date for payment of Final Dividend

  • Piramal Pharma - Record Date

    13 Jun 2025, 5:59PM Piramal Pharma Limited has informed the Exchange that Record date for the purpose of DI is 16-Jul-2025.

  • Piramal Pharma - Intimation Of 5Th Annual General Meeting To Be Held On Wednesday, July 30, 2025

    13 Jun 2025, 5:57PM Intimation of Annual General Meeting to be held on Wednesday, July 30, 2025

  • Piramal Pharma - General Updates

    13 Jun 2025, 5:56PM Intimation of Annual General Meeting and Record Date for payment of Final Dividend

  • Piramal Pharma - General Updates

    13 Jun 2025, 5:51PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ( SEBI Listing Regulations )

  • Piramal Pharma - Change in Auditors

    13 Jun 2025, 5:49PM Piramal Pharma Limited has informed the Exchange regarding Change in Auditors of the company.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

    13 Jun 2025, 5:48PM Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('SEBI Listing Regulations')

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    2 Jun 2025, 12:31PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - General Updates

    2 Jun 2025, 10:44AM Piramal Pharma Limited has informed the Exchange about General Updates

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 Jun 2025, 12:28PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - General Updates

    26 May 2025, 4:31PM Piramal Pharma Limited has informed the Exchange about Annual Secretarial Compliance Report for the year ended 31st March, 2025

  • Piramal Pharma - Alteration Of Capital and Fund Raising-XBRL

    21 May 2025, 3:30PM Piramal Pharma Limited has informed the Exchange regarding Allotment of Securities

  • Piramal Pharma - ESOP/ESOS/ESPS

    21 May 2025, 3:24PM Piramal Pharma Limited has informed the Exchange regarding Allotment of 3500000 Shares.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 May 2025, 3:28PM Please refer attachment

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    16 May 2025, 4:47PM Piramal Pharma Limited has informed the Exchange about Transcript

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    16 May 2025, 4:44PM Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2025

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    15 May 2025, 3:04PM Piramal Pharma Limited has informed the Exchange about Link of Recording

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    15 May 2025, 2:58PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March, 2025

  • Piramal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    14 May 2025, 9:34PM PIRAMAL PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen

  • Piramal Pharma - Outcome of Board Meeting-XBRL

    14 May 2025, 9:32PM Piramal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on 14-May-2025 for Dividend

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Dividend Updates

    14 May 2025, 8:59PM Please refer attachment

  • Piramal Pharma - Investor Presentation

    14 May 2025, 8:57PM Piramal Pharma Limited has informed the Exchange about Investor Presentation

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Change in Directorate

    14 May 2025, 8:57PM Please refer attachment

  • Piramal Pharma - Press Release

    14 May 2025, 8:56PM Piramal Pharma Limited has informed the Exchange regarding a press release dated May 14, 2025, titled ""Press Release and Investor Presentation Audi

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    14 May 2025, 8:56PM Please refer attachment

  • Piramal Pharma - Resignation

    14 May 2025, 8:54PM Piramal Pharma Limited has informed the Exchange regarding Resignation of Mr. Neeraj Bharadwaj as Non- Executive Director of the company w.e.f. May 1

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    14 May 2025, 8:54PM Please refer attachment

  • Piramal Pharma - Appointment

    14 May 2025, 8:53PM Piramal Pharma Limited has informed the Exchange regarding Appointment of Mr. Amit Jain as Non- Executive Director of the company w.e.f. May 14, 2025

  • Piramal Pharma - Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March, 2

    14 May 2025, 8:52PM Please refer attachment

  • Piramal Pharma - Change in Director(s)

    14 May 2025, 8:51PM Piramal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Piramal Pharma Q4 net profit up 1.53% at Rs 277.27 cr

    14 May 2025, 8:50PM The company reported standalone net profit of Rs 277.27 crore for the quarter ended March 31, 2025 as compared to Rs 273.08 crore in the same period l

  • Piramal Pharma - Outcome of Board Meeting

    14 May 2025, 8:50PM Piramal Pharma Limited has informed the Exchange regarding Board meeting held on May 14, 2025.

  • Piramal Pharma - Dividend

    14 May 2025, 8:49PM Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of 0.14 per e

  • Piramal Pharma - Dividend

    14 May 2025, 8:48PM Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 0.14 p

  • Piramal Pharma - Outcome of Board Meeting

    14 May 2025, 8:46PM Piramal Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.

  • Piramal Pharma - Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited ('Company') Held On 14Th\r\nMay

    14 May 2025, 8:46PM Please refer attachment

  • Piramal Pharma - Capacity addition

    12 May 2025, 5:02PM Piramal Pharma Limited has informed the Exchange about Capacity addition

  • Piramal Pharma - General Updates

    12 May 2025, 11:03AM Piramal Pharma Limited has informed the Exchange about Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at T

  • Piramal Pharma - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 20

    12 May 2025, 11:00AM Sucessful closure of US FDA Inspection at Piramal Pharma's Manufacturing Facility located at Turbhe.

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    5 May 2025, 6:28PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 May 2025, 6:22PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Trading Window-XBRL

    29 Apr 2025, 5:26PM PIRAMAL PHARMA LIMITED has informed the Exchange about Closure of Trading Window

  • Piramal Pharma - Board Meeting Intimation

    29 Apr 2025, 5:23PM PIRAMAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 14-May-2025 to consider and approve the Yearly Audited Financial re

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2025, 5:22PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Apr 2025, 5:07PM Intimation of Conference Call with Investor/Analysts under the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

  • Piramal Pharma - Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Bo

    29 Apr 2025, 5:00PM Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and a

  • Piramal Pharma - Acquisition-XBRL

    23 Apr 2025, 9:54PM Piramal Pharma Limited has informed the Exchange regarding Acquisition

  • Piramal Pharma - Acquisition

    23 Apr 2025, 9:52PM Piramal Pharma Limited has informed the Exchange about Acquisition

  • Piramal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    21 Apr 2025, 4:20PM As of March 2025, 34.94% is owned by Indian Promoters, 64.71% by Public and 0.34% by Non Promoters-Non Public. <p align=justify> Institutional holds 4

  • Piramal Pharma - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclo

    1 Apr 2025, 10:30PM Disclosure under Regulation 30 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) regulations, 2015 (\SEB

  • Piramal Pharma - Commencement of commercial production/operations

    1 Apr 2025, 10:26PM Piramal Pharma Limited has informed the Exchange about Commencement of commercial production/operations

  • Piramal Pharma

    21 Mar 2025 , 10:19AM Piramal Pharma arm gets market authorization for Neoatrico from United Kingdom’s Medicines and Healthcare Products Regulatory Agency. Neoatrico is a paediatric solution used in treatment for hypotension in neonates, infants, and children. Positive

  • Piramal Pharma

    19 Feb 2025 , 10:26AM Piramal Pharma: The US FDA issued Form 483 with six observations for the company’s Turbhe facility.

  • Piramal Pharma

    23 Jan 2025 , 9:39AM Piramal Critical Care launches Chlorpromazine Hydrochloride in US. With this launch, company continues to expand their generic injectables portfolio.

  • Piramal Pharma

    18 Apr 2024 , 11:50AM The US FDA had Inspected Piramal Pharma’s manufacturing facility located at Riverview, USA and has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the US FDA. Positive

  • Piramal Pharma

    26 Feb 2024 , 12:37PM The US FDA conducted a Pre-Approval Inspection (PAI) inspection of Piramal Pharma Limited's Lexington (USA) facility from 20th February, 2024 to 23rd February, 2024 for one of the product expected to be manufactured at this facility. On conclusion of the inspection, a Form-483 was issued with 2 observations. The observations does not pose any risk to site’s compliance standards or its business continuity. The Company is preparing a detailed response to said observations, which will be submitted to the US FDA within stipulated timelines. (Positive).

  • Piramal Pharma

    17 Jan 2024 , 9:37AM Piramal Critical Care division has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the United States of America. The launch will enable PCC to further expand their zinc sulphate existing product line and overall generic injectable portfolio. Positive
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Piramal Pharma Ltd stock 

Name March-25 March-24 March-23 March-22
Assets 8674.47 7863.96 6889.07 6168.87
Liabilities 8674.47 7863.96 6889.07 6168.87
Equity 1324.35 1322.95 1193.32 1185.91
Gross Profit 1040.44 617.92 97.53 397.3
Net Profit 691.4 391.22 69.5 343.05
Cash From Operating Activities 548.77 358.29 71.52 255.2
NPM(%) 13.08 8.91 2.01 11.08
Revenue 5285.71 4390.11 3443.22 3094.95
Expenses 4245.27 3772.19 3345.69 2697.65
ROE(%) 8.73 4.94 0.87 4.33

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Jul 2025 0.14 1.4 0 219.04
12 Jul 2024 0.11 1.1 0 150.45

Peers

Other companies within the same industry or sector that are comparable to Piramal Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 877.60 4.96 29.12 116.08 301.39 0.57
Lotus Eye Hospital and Institute Ltd 71.05 -0.15 203.00 423.00 3.55 0.00
Vaishali Pharma Ltd 11.55 -0.43 192.50 218.03 3.13 0.00
Astec Lifesciences Ltd 943.00 1.98 0.00 398.85 -687.10 0.00

Company Info

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Read More

Parent Organisation

Piramal Pharma Ltd.

Founded

04/03/2020

Managing Director

NSE Symbol

PPLPHARMAEQ

FAQ

The current price of Piramal Pharma Ltd is ₹ 203.59.

The 52-week high for Piramal Pharma Ltd is ₹ 205.00 and the 52-week low is ₹ 201.12.

The market capitalization of Piramal Pharma Ltd is currently ₹ 27062.16. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Piramal Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Piramal Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Piramal Pharma Ltd shares.

The CEO of Piramal Pharma Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT